We’re proud to announce a $200 million private financing to fuel the next chapter for Star Therapeutics. Building on the momentum of this year, including the acquisition of Star subsidiary Vega Therapeutics, this financing will support our next-generation pipeline as we advance preclinical programs into the clinic and continue expanding into new areas of significant unmet need. Our mission hasn’t changed: developing best-in-disease therapies for the millions of patients who need them. Listen in below as CEO Adam Rosenthal shares details. Read more here. star-therapeutics.com/star-t…

Today, we announced an upcoming oral presentation of complete safety & efficacy data on all patients from the Phase 1/2 multidose study of VGA039 for VWD, along with additional presentations on the program at #ISTH2026 being held July 11-15 in Paris. More: star-therapeutics.com/star-t…

We spent the weekend in Florida at @VwdConnect's Severe VWD Conference. We connected with patients, families & providers from across the U.S & shared our newest bleeding resource designed to help people recognize how VWD affects their daily lives & better advocate for their care.

For many, VWD symptoms begin long before diagnosis. Frequent nosebleeds at school, playground injuries, & growing up knowing your body responds differently can force patients to navigate uncertainty from a young age. Matt & Heather reflect on their early memories managing bleeds.

Team member Laura Guido visited Wisconsin this weekend for the @WIBloodDisorder conference. It was a meaningful opportunity to spend time with members of the bleeding disorders community and hear firsthand about the experiences that shape and inspire our work in VWD.

Today, we announced we've entered into a definitive agreement for @Incyte to acquire Vega Therapeutics for up to $2.0 billion. The proposed acquisition would add VGA039 to Incyte's hematology portfolio. More: investor.incyte.com/news-rel…

Have you or your loved one been diagnosed with #vonWillebrandDisease? You may be eligible for the VIVID Phase 3 clinical trial. Learn more about our investigational medicine, VGA039, below and visit our website to connect with us for more. star-therapeutics.com/connec…

"Are yours this heavy?" For many women & girls with VWD, prolonged menstrual cycles are often dismissed as something they must “just deal with.” From a young age, avoiding events & managing severe symptoms becomes normal. Stephanie shares her story during #MenstrualHealth Month.

Clinical trials aren't just about data, they're about people. Participation in research is often part of a larger journey shaped by advocacy & a desire to improve care advances. Patients' voices are critical to this work. Thanks to all contributing to progress for our community.

According to @ACOG, heavy menstrual bleeding affects nearly all women with VWD. Cycles can often last for weeks at a time, require constant management & can lead to anemia. This #MenstrualHealth Month, stories like Jessica’s help bring visibility to stories that often go unheard.

We invite everyone impacted by VWD to join us for @nbd_foundation's Wednesday Webinar series this week to learn more about our investigational therapy, VGA039. Clinical development lead, Ben Kim, looks forward to sharing updates on the program. Register: hemophilia-org.zoom.us/webin…

For those with VWD, the emotional toll of uncertainty, dismissal & hopelessness can be just as burdensome as the physical symptoms. During #MentalHealthAwarenessMonth, Matt shares the lifelong impact living with VWD has had on his mental health & navigating depression & anxiety.

VWD often hides in plain sight - passed quietly through generations, undiagnosed & misuderstood. A reminder that genetics isn't abstract, its the key to finding patients who've been missed for decades. Earlier diagnosis, better outcomes. It starts with understanding. #WorldDNADay

Thank you to our global bleeding disorders community for a great week in Kuala Lumpur at #WFHCongress2026! Bravo to the WFH team for elevating dialogues around unmet needs in VWD, with a special emphasis on bleeding considerations for women and girls with bleeding disorders.

We’re pleased to announce the FDA has granted Rare Pediatric Disease Designation & Breakthrough Therapy Designation to VGA039 for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients w/ #VWD. Hear from CMO Dr. Gary Patou. star-therapeutics.com/star-t…

We enjoyed supporting Hemophilia Foundation of Michigan’s VWD Symposium & SpringFest, a meaningful opportunity to listen to and learn from the bleeding disorders community. Thank you to HFM for bringing the community together for inspiring conversations & meaningful connections.

On #WorldHemophiliaDay, we celebrate the impact that advances in treating hemophilia have had on patients’ lives. We're working to advance similar innovation for the VWD community & are committed to helping ensure every person with a bleeding disorder is seen, heard & supported.

Our team is excited to be heading to Kuala Lumpur for #WFHCongress2026 next week. See below for details on where we'll be sharing the latest on Star and VGA039 throughout the week. We look forward to connecting with the global bleeding disorders community.

While innovation in other #bleedingdisorders has advanced rapidly, innovation in VWD has lagged behind for decades. As we close out Bleeding Disorders Awareness Month, patients Heather & Z share a message of hope for innovation for the VWD community.